Advertisement
Screener

Benitec Biopharma Inc. (BNTC) Overview

Benitec Biopharma Inc. (BNTC) Overview

  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.24; Beat / miss (m).
  • 1 Oct 2025: Period ending 31 Dec 2025; Estimate (m); Actual -0.26; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.22; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.21; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$9.07$10.00$11.03$12.17$13.41$14.792025-11-062026-11-06$1.83$3.73$7.59$15.46$31.47$64.082021-11-082026-11-06$1.83$6.59$23.67$85.04$305.54$1,097.772016-11-072026-11-06$1.83$9.32$47.34$240.57$1,222.45$6,211.802014-06-242026-11-06$1.83$9.32$47.34$240.57$1,222.45$6,211.802014-06-242026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$9.55
Previous close
$9.75
Change
-$0.20
Change (%)
-2.05%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

BNTC
-27.72%
S&P 500
(m)

1 year

BNTC
-30.41%
S&P 500
(m)

3 years

BNTC
+221.78%
S&P 500
(m)

5 years

BNTC
-83.63%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

31 Mar 2026 ○ Estimate (m) ● Actual -0.24

-0.46-0.35-0.24-0.14-0.0331 Mar 2025: estimate (m); actual -0.3831 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.2130 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.2230 Sept 2025(m)31 Dec 2025: estimate (m); actual -0.2631 Dec 2025(m)31 Mar 2026: estimate (m); actual -0.2431 Mar 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202631 Mar 2026(m)-0.24(m)(m)
1 Oct 202531 Dec 2025(m)-0.26(m)(m)
1 Jul 202530 Sept 2025(m)-0.22(m)(m)
1 Apr 202530 Jun 2025(m)-0.21(m)(m)
1 Jan 202531 Mar 2025(m)-0.38(m)(m)

30 Jun 2026 ○ Estimate (m) ● Actual -0.98

-37.96-28.67-19.38-10.09-0.8030 Jun 2022: estimate (m); actual -37.8830 Jun 2022(m)30 Jun 2023: estimate (m); actual -14.1230 Jun 2023(m)30 Jun 2024: estimate (m); actual -1.2230 Jun 2024(m)30 Jun 2025: estimate (m); actual -1.0530 Jun 2025(m)30 Jun 2026: estimate (m); actual -0.9830 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jul 202530 Jun 2026(m)-0.98(m)(m)
1 Jul 202430 Jun 2025(m)-1.05(m)(m)
1 Jul 202330 Jun 2024(m)-1.22(m)(m)
1 Jul 202230 Jun 2023(m)-14.12(m)(m)
1 Jul 202130 Jun 2022(m)-37.88(m)(m)

Revenue vs. Earnings

USD

31 Mar 2026 ■ Revenue 0.00M ■ Earnings -11.94M — Profit margin (m)

-16.24M-10.25M-4.25M1.74M31 Mar 2025: revenue 0.00M; earnings -14.50M; profit margin (m)31 Mar 202530 Sept 2025: revenue 0.00M; earnings -8.96M; profit margin (m)30 Sept 202531 Dec 2025: revenue 0.00M; earnings -11.84M; profit margin (m)31 Dec 202531 Mar 2026: revenue 0.00M; earnings -11.94M; profit margin (m)31 Mar 2026

30 Jun 2021 ■ Revenue 0.06M ■ Earnings -13.88M — Profit margin -23528.81%

-17.01M-23529.8%-6.23M-15679.1%4.55M-7828.3%15.33M22.4%30 Jun 2019: revenue 12.20M; earnings 2.61M; profit margin 21.39%30 Jun 201930 Jun 2020: revenue 0.10M; earnings -8.27M; profit margin -8111.76%30 Jun 202030 Jun 2021: revenue 0.06M; earnings -13.88M; profit margin -23528.81%30 Jun 2021

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$9.55(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$9.55High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning BNTC

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 31 Mar 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-41.54M
Profit margin
(m)
Return on assets · 12 month
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
158.91K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-10.88%*
Total return · month
-21.88%*
Total return · quarter
-23.29%*
Total return · half year
-5.16%*
Total return · year to date
-27.72%*
Total return · 1 year
-30.41%*
Total return · 3 years
221.78%*
Total return · 5 years
-83.63%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Benitec Biopharma Inc. Overview

View more →

(m)

(m)

SEC CIK
1808898
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
3940 TRUST WAY, HAYWARD, California, 94545, United States
Fiscal year end
0630
Phone
(510) 780-0819

Similar stocks

Stock NameCountryMarket CapPE Ratio
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Vogenx, Inc. (VOGX)United States$0.355B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58